EFFECTS OF NEBIVOLOL VS NADOLOL ON GLUCOSE AND LIPID METABOLISM IN OVERWEIGHT HYPERTENSIVE PATIENTS. A OPEN RANDOMIZED CONTROLLED STUDY

Objective. The aim of the present study was to assess effects of treatment of overweight hypertensive patients with vasodilatating and non-vasodilatating beta-blockers on glucose and lipid metabolism.

Patients and methods. 24 patients with mild to moderate hypertension were randomised into two treatment groups - nebivolol 5-10 mg per day vs nadolol 80-240 mgper day and treated for 6 months. Oral glucose tolerance test (OGTT) with the measurement of glucose and insulin levels: fasting, 30, 60, 90 and 120 minutes of test were performed initially and at the end of the study. Lipid profile and ambulatory blood pressure monitoring were also assessed for all patients.

Results. Antihypertensive effect was comparable in both groups. At the same time, nebivolol improved parameters of OGTT and reduced insulin resistance, while in nadolol group these parameters remained unchanged. Lipid profile improved during nebivolol treatment and slightly worsened in nadolol group.

Conclusion. Long-term nebivolol treatment can improve glucose tolerance and lipid spectrum in overweight patients, while administration of nadolol can slightly worsen lipid metabolism. These effects are unrelated to antihypertensive action of the drugs, which is comparable.

1. Messerli F.H., Grossman E., Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-7.

2. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.

3. Pollare T., Lithell H., Selinus I., et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989; 298: 1152-7.

4. Lithell H., Pollare T., Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992; 1: 92-101.

5. Haenni A., Lithell H. Treatment with a betablocker with b2-agonism improves glucose and lipid Metabolism in essential hypertension. Metabolism 1994; 43: 455-61.

6. Jacob S., Rett K., Wicklmayr M., et al. Differential effect of chronic treatment with two betablocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14: 489-94.

7. Interim publication of results: The ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-75.

8. Thulin T., Lehtonen A., Dahlof C., et al. Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group. Int J Clin Pharmacol Ther 1999; 37 (1): 28-33.

9. Lakshman M.R., Reda D.J., Materson B.J., et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999; 159 (6): 551-8.

10. Jacob S., Balletshofer B., Henriksen E.J., et al. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 1999; 8 (5-6): 261-8.

11. Seltzer S., Allen W., Herron A., et al. Insulin secretion in response to glycemic stimulus. J Clin Invest 1967; 40 (3): 323-35.

12. Matthew D.R., Hosker J.P., Rudeuski A.S., et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

13. Климов А.Н., Ганелина И.Е. Фенотипирование гиперлипидемий. М.: Медицина, 1975. 47с.

14. Kiens В., Lithell Н., Mikines K.J., Richter Е.A. Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relations to insulin action J Clin Invest 1989; 84: 1124-9.

15. Grimm R.H. Antihypertensive therapy: taking lipids into consideration. Am Heart J 1991; 122: 910-18.

16. Weber M.A. Hypertension with concomitant conditions: the changing role of b-adrenoreceptor blockade. Am Heart J 1991; 122: 716-23.

17. Rabkin S.W. Mechanisms of action of adrenergic receptor blockers on lipids during antihipertensive drug treatment J Clin Pharmacol 1993; 33: 286-91.

18. Superko H.R., Haskell W.L., Krauss R.M. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Arteriosclerosis 1993; 101: 1-8.

19. DeFronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia. Diabetes Care 1991; 14: 173-7.

20. Lind L., Berne C., Pollare, Lithell H. Metabolic effect of isradipine as monotherapy or in combination with pindolol during long-term anti-hypertensive treatment. J Intern Med 1994; 236: 37-42.

21. Reneland R., Alvarez E., Andersson P.E., et al. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14 (3): 175-80.

22. Rossner S., Taylor C.L., Byinglon R.P., Furberg C.D. Long term propranolol treatment and changes in body weight after myocardial infarction. Brit Med J 1990; 300: 902-3.

23. Lund-Johansen P., Omvik P., Nordrehaug J.E. Long-term haemodynamic effects of antihypertensive treatment. Clin Invest 1992; 70: S58-64.

24. Malminiemi K. Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Therapy 1995; 9: 295-304.

25. Jacob S., Rett K., Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11 (10): 1258-65.